Literature DB >> 15882432

Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype.

V Rao1, N Dhar, H Shakila, R Singh, A Khera, R Jain, M Naseema, C N Paramasivan, P R Narayanan, V D Ramanathan, A K Tyagi.   

Abstract

Mycobacterium tuberculosis can not only neutralize immune effector functions, but also has the ability to modulate host-signalling cascades involved in the development of these responses. The 19 kDa antigen (Rv3763), a lipoprotein of M. tuberculosis, elicits high levels of interleukin (IL)-12 from macrophages in addition to its powerful immunomodulatory properties, leading to suppression of antigen-presentation signalling cascades. The present study was aimed at analysing the effect of overexpression of this antigen on the immunostimulatory properties of M. bovis Bacille Calmette-Guerin (BCG). We have constructed a recombinant BCG strain (rBCG19N) producing higher levels of the 19 kDa antigen in both the cytoplasmic (approximately eightfold) and extracellular (approximately fivefold) fractions as compared to the wildtype BCG. Immunization of mice with rBCG19N elicited high levels of interferon-gamma (IFN-gamma) and relatively low levels of IL-10 against the purified 19 kDa antigen. However, in response to total BCG sonicate, mice immunized with rBCG19N produced significantly high levels of IL-10 with relatively very low levels of IFN-gamma. This polarization of the host immune responses towards T-helper 2 subtype resulted in complete abrogation of the protective efficacy of BCG, when rBCG19N was used as a live vaccine against M. tuberculosis challenge in guinea pigs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882432     DOI: 10.1111/j.1365-3083.2005.01569.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes.

Authors:  Saet-Byel Jung; Chul-Su Yang; Ji-Sook Lee; A-Rum Shin; Sung-Soo Jung; Ji Woong Son; Clifford V Harding; Hwa-Jung Kim; Jeong-Kyu Park; Tae-Hyun Paik; Chang-Hwa Song; Eun-Kyeong Jo
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 3.  Lipoproteins of bacterial pathogens.

Authors:  A Kovacs-Simon; R W Titball; S L Michell
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

4.  Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.

Authors:  Denise Morais da Fonseca; Célio Lopes Silva; Marina Oliveira e Paula; Edson Garcia Soares; Gilles Marchal; Cynthia Horn; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2007-04-13       Impact factor: 7.397

5.  TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis.

Authors:  Scott M Reba; Qing Li; Sophia Onwuzulike; Xuedong Ding; Ahmad F Karim; Yeritza Hernandez; Scott A Fulton; Clifford V Harding; Christina L Lancioni; Nancy Nagy; Myriam E Rodriguez; Pamela A Wearsch; Roxana E Rojas
Journal:  Eur J Immunol       Date:  2014-03-14       Impact factor: 5.532

Review 6.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

7.  A mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo but retains potent vaccinogenic properties.

Authors:  Marcela Henao-Tamayo; Ana Paula Junqueira-Kipnis; Diane Ordway; Mercedes Gonzales-Juarrero; Graham R Stewart; Douglas B Young; Robert J Wilkinson; Randall J Basaraba; Ian M Orme
Journal:  Vaccine       Date:  2007-08-13       Impact factor: 3.641

8.  Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B.

Authors:  Chun Wang; Ruiling Fu; Zhenhua Chen; Kun Tan; Lingxia Chen; Xindong Teng; Jia Lu; Chunwei Shi; Xionglin Fan
Journal:  Clin Dev Immunol       Date:  2012-04-18

9.  Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses.

Authors:  Anat Zvi; Naomi Ariel; John Fulkerson; Jerald C Sadoff; Avigdor Shafferman
Journal:  BMC Med Genomics       Date:  2008-05-28       Impact factor: 3.063

Review 10.  Tuberculosis-Cancer Parallels in Immune Response Regulation.

Authors:  Thomas E Bickett; Sana D Karam
Journal:  Int J Mol Sci       Date:  2020-08-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.